- Cybin names Dr. Amir Inamdar as chief medical officer for European operations
- The company appoints Dr. Geoff Varty as head of research and development
- Both professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics
As Cybin (NEO: CYBN) (NYSE American: CYBN) continues its commitment to focus on the psychedelic therapeutic space and deliver proprietary drug-discovery platforms, the company has made key additions and changes (https://ibn.fm/0GBMQ). Most recently the company has appointed two new executives and announced internal promotions to continue strengthening its leadership team.
Cybin has named Dr. Amir Inamdar as chief medical officer for European operations and Dr. Geoff Varty as head of research and development for the company. In addition, the company announced the promotion of Lori Challenger to chief compliance, ethics and administrative officer and Robert Mino to general counsel.
A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug development experience, Dr. Amir Inamdar has garnered invaluable experience in progressing several drugs from preclinical development to early-phase clinical trials; he also has key experience in designing and delivering proof-of-concept studies as well as leading teams through marketing authorization applications.
Inamdar’s background stretches across diverse psychiatric indications, including schizophrenia, depression, bipolar disorder, treatment-resistant mental illnesses and substance-use disorders. He has led multidisciplinary teams, providing strategic direction and clinical and scientific leadership. Inamdar has also received numerous awards for his research and development work in clinical drug development.
Inamdar has worked at GlaxoSmithKline, Takeda Pharmaceutical Company Limited and AstraZeneca. In his roles at these organizations, he developed a network of excellence in psychiatry and provided medical leadership to enable the development of candidate drugs from selection through to proof-of-concept trials across a variety of central nervous system indications. He was also key in successfully obtaining marketing authorization for an antipsychotic in Europe, progressing small molecules from candidate selection to first in-human studies, and leading clinical teams in treatment of resistant depression, narcolepsy and anxiety.
Varty too brings an impressive history of work expertise. A highly experienced neuroscientist and drug discoverer, Varty also has a track record of progressing novel molecular entities into clinical trials and to the patient. With a bachelor’s degree in pharmacology and a PhD in neuropsychopharmacology, Varty has focused his research on the development of behavioral models for psychosis and cognition, along with the preclinical testing of novel compounds. He has spent his two-decade career in the pharmaceutical industry, working in R&D and scientific leadership and managerial roles at Schering Plough, Sanofi and Merck.
While at these companies, Varty led in-vivo research in several central nervous system–related areas such as pain, anxiety, depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. He has also gained invaluable experience collaborating with cross-functional teams working together toward focused objectives. He has published more than 130 journal articles and abstracts.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.